Anti-ILT4 Monoclonal Antibody MK-4830 clinical trials
Also written MK-4830.
How each study uses Anti-ILT4 Monoclonal Antibody MK-4830 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-ILT4 Monoclonal Antibody MK-4830 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MK-4830
- 12
Studies by the year they started
13 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Merck Sharp & Dohme LLC (12) · Presage Biosciences (1)
Often tested with
Tested in the same studies.
Rolistobart (4) · Pembrolizumab/Quavonlimab MK-1308A (3) · Favezelimab (3) · Vibostolimab (3) · Boserolimab (3) · Favezelimab/Pembrolizumab Formulation (2) · Raludotatug deruxtecan (1) · Belzutifan (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-ILT4 Monoclonal Antibody MK-4830.
Studies
Open first, then newest update. How each study uses Anti-ILT4 Monoclonal Antibody MK-4830 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as MK-4830How we knowReport a problem
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT05319730Written as MK-4830How we knowReport a problem
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).CompletedPhase 2Merck Sharp & Dohme LLCNCT04895722Written as MK-4830How we knowReport a problem
- KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)CompletedPhase 2Merck Sharp & Dohme LLCNCT04165083Written as MK-4830How we knowReport a problem
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04626518Written as MK-4830How we knowReport a problem
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04303169Written as MK-4830How we knowReport a problem
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)CompletedPhase 2Merck Sharp & Dohme LLCNCT04924101Written as MK-4830How we knowReport a problem
- KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)CompletedPhase 2Merck Sharp & Dohme LLCNCT04165096Written as MK-4830How we knowReport a problem
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT04938817Written as MK-4830How we knowReport a problem
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT05342636Written as MK-4830How we knowReport a problem
- Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT03564691Written as MK-4830How we knowReport a problem
- Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)CompletedPhase 2Merck Sharp & Dohme LLCNCT05446870Written as MK-4830How we knowReport a problem
- PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSCompletedEarly Phase 1Presage BiosciencesNCT06413095Written as MK-4830 + PembrolizumabHow we knowReport a problem
Tested with established drugs · 1 — they are given beside it
Tested in a combination · 12 — another drug in the study is under test too
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as MK-4830How we knowReport a problem
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT05319730Written as MK-4830How we knowReport a problem
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).CompletedPhase 2Merck Sharp & Dohme LLCNCT04895722Written as MK-4830How we knowReport a problem
- KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)CompletedPhase 2Merck Sharp & Dohme LLCNCT04165083Written as MK-4830How we knowReport a problem
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04626518Written as MK-4830How we knowReport a problem
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04303169Written as MK-4830How we knowReport a problem
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)CompletedPhase 2Merck Sharp & Dohme LLCNCT04924101Written as MK-4830How we knowReport a problem
- KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)CompletedPhase 2Merck Sharp & Dohme LLCNCT04165096Written as MK-4830How we knowReport a problem
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT04938817Written as MK-4830How we knowReport a problem
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT05342636Written as MK-4830How we knowReport a problem
- Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT03564691Written as MK-4830How we knowReport a problem
- PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSCompletedEarly Phase 1Presage BiosciencesNCT06413095Written as MK-4830 + PembrolizumabHow we knowReport a problem
What changed recently
From the registry's own updates since Oct 22, 2026.